About Us

Orbit Biomedical’s mission is to revolutionize gene and cell therapy treatment by setting a new standard for precise, targeted surgical delivery. Our focus is to transform the accuracy, safety and consistency of delivering therapeutics to patients suffering from sight-threatening diseases. Located in Philadelphia, Orbit Biomedical was founded in 2018 with a Series A investment from Syncona, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.  In 2019, Orbit Biomedical became part of Gyroscope Therapeutics, a UK based company developing gene therapies for certain retinal conditions. We are developing technology* that is focusing on:
Precision and accuracy Building upon years of biomedical engineering, our research and development is focused on optimizing the precision and accuracy of delivery to the subretinal space, which may be useful for the treatment of blinding eye diseases. Safety Our goal is to help make the administration of one-time therapies as safe and efficient as possible for patients. To achieve this goal, in addition to applying our technology to Gyroscope Therapeutics’ programs, we aim to collaborate with partners who are developing therapies to preserve or restore vision in patients suffering from sight-threatening ophthalmic diseases. Consistency An important focus of our research is to minimize variability in delivery of therapeutics. We believe that once our technology is approved for commercial use, this will bring value to patients and surgeons and help to ensure scalability. * Our technology is under development and our device is currently not approved for sale.  

Our Leadership Team

The Gyroscope Leadership Team

The Team

Orbit Biomedical is developing surgical devices and procedures designed to deliver one-time therapies to the subretinal space. Our team brings years of expertise in biomedical engineering, medical device development and clinician training to ophthalmology.  The joint Gyroscope Therapeutics and Orbit Biomedical teams are able to harness this best-in-class surgical ocular delivery alongside cutting-edge technology in order to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system.